BusinessQIAGEN Board Expected to Review EQT Offer Above $50 a ShareBy Helena WardOct 21, 2026, 11:04 AM UTC
HealthAignostics Launches HETA Clinical Tools Without Test-Outcome DataBy Naomi CalderOct 16, 2026, 10:49 PM UTC